co.
uk Tuesday 02 January 2018 Advertisement Cancer drug development time halved thanks to artificial intelligence Artificial intelligence has halved the time it has taken to bring a cancer combatting drug to market, start-up claims Blood tests could identify an increased risk of breast cancer long before mammograms can spot it, research suggests The drug can help cells metabolise glucose again, letting them die off Ian Douglas By Ian Douglas 9:46AM BST 09 Oct 2015 Follow A cancer-fighting drug is on target to be brought to market in half the expected time thanks to the use of artificial inteligence in testing, a start up has claimed.
 Berg Health, a pharmaceutical startup founded in 2008 with Silicon Valley venture capital backing, said it expected the drug to go on sale within three years, marking seven years in development compared to the general 14.
--
 Berg’s drug, BPM31510, will reactivate the mitochondria, restarting the metabolising of glucose as normal and reinstituting cell death, so the body can harmlessly pass the problem cells out of the body.
 Berg Health's team used a specialised form of artificial intelligence to compare samples taken from patients with the most aggressive strains of cancer, including pancreatic, bladder and brain, with those from non-cancerous individuals.
 The technology highlighted disparities between the corresponding biological profiles, selecting those it predicted would respond best to the drug.